ClinicalTrials.gg
RecruitingNCT06032065Updated Apr 15, 2026

SMART Exercise for PAD

A Phase 3 interventional study of Supervised Treadmill Exercise and Home-Based Exercise in Peripheral Arterial Disease, Aging and Peripheral Vascular Diseases, sponsored by Northwestern University. Recruiting at 3 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Northwestern University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Peripheral Arterial Disease by Northwestern University — 8 open to participants now, 10 under way, 4 of them phase 3. Peripheral Arterial Disease · Northwestern University.

Planned enrollment
6th of 24
210 · median 192
Started
2023
with 1 other
Phase 3
7 of 26
4 open now
Registered
20th of 26
by date

Among the 26 studies in Peripheral Arterial Disease by Northwestern University, this one is the 6th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 20th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

8 of the 26 studies in Peripheral Arterial Disease by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Peripheral Arterial Disease by Northwestern University, or all of them as a file.
02

Study summary

Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times/week to a center for SET is burdensome. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. Walking exercise is first line therapy to improve walking distance for PAD, but it does not eliminate ischemic leg symptoms in most people with PAD. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. The investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. Participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.

Read the detailed description

Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times/week to a center for SET is burdensome. As of 2018, only 1.3% of patients with Medicare and symptomatic PAD had enrolled in SET. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. In 2021, the investigators reported that a home-based exercise intervention that incorporated behavioral methods significantly improved six-minute walk in PAD, compared to an attention control group. But no randomized trials have compared SET to a home-based exercise intervention that incorporated behavioral change methods in PAD. However, 45% of people with PAD do not meaningfully respond to exercise interventions, defined as failure to improve six-minute walk by > 20 meters. This phenomenon occurs for both supervised and home-based exercise. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. Therefore, the investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. In this 2 x 2 factorial design, participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.

03

Conditions studied

  • Peripheral Arterial Disease
  • Aging
  • Peripheral Vascular Diseases
  • Walking, Difficulty

Keywords

  • behavior change
  • patient reported outcome measure
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as either:

  1. An ABI \<= 0.90 at baseline.
  2. Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.
  3. An ABI of >0.90 and \<1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.

Exclusion criteria

Exclusion Criteria:

  1. Above- or below-knee amputation
  2. Limb-threatening ischemia defined as an ABI \<0.40 with symptoms of rest pain
  3. Wheelchair confinement or requiring a walker to ambulate
  4. Walking is limited by a condition other than PAD
  5. Current foot ulcer on bottom of foot
  6. Unwilling to drink beetroot juice
  7. Unwilling to accept randomization into either group (home based exercise or supervised exercise)
  8. Planning to engage in new walking exercise outside of the study or unwilling to refrain from new walking exercise activity during the trial.
  9. Already exercising at a level consistent with exercise intervention.
  10. End-stage kidney disease (ESKD) associated with the need for dialysis.
  11. Planned major surgery, coronary or leg revascularization during the next six months
  12. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  13. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
  14. Mini-Mental Status Examination () score \< 23 or dementia. However, if the MMSE is \< 23 and the Principal Investigator evaluation determines that the lower score is related to language barriers or education level, the Principal Investigator has discretion to allow a participant with MMSE \< 23 to participate, as appropriate.
  15. Allergy to beetroot juice
  16. Currently consuming beetroot juice or oral nitrate or nitrite, or a beetroot supplement, and/or unwilling to avoid these during study participation. Participants currently consuming one cup of beets daily will be asked to discontinue beet ingestion for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more, they will not be eligible for the clinical trial.
  17. Unstable angina
  18. Abnormal baseline stress test without subsequent clearance for exercise by physician
  19. Non-English speaking. The SMART PAD interventions are delivered by interventionists who do not speak non-English languages. The integrity of the clinical trial requires clear and effective communication for data collection and intervention delivery. The trial does not have staff members who are fluent in non-English languages, nor does it have the ability to translate all study materials into other languages.
  20. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.] Participants in a study that involved up to three single doses of nitrate-rich beetroot juice administered on separate days may participate if a month has passed since their last dose of nitrate-rich beetroot juice.
  21. Visual impairment that limits walking ability.
  22. Baseline blood pressure \<100/45.
  23. Participation in a supervised treadmill exercise program or cardiac rehabilitation program in previous three months.
  24. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
  25. An value \<30 or potassium >5.0.
  26. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
  27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Supervised treadmill exercise + nitrate rich beetroot juice

    This group will be participating in Supervised Treadmill Exercise and drinking nitrate rich beetroot juice for 12 weeks.

    Behavioral: Supervised Treadmill Exercise · Dietary Supplement: Nitrate-rich beetroot Juice

  • Placebo comparator
    Supervised treadmill exercise + placebo

    This group will be participating in Supervised Treadmill Exercise and drinking placebo beetroot juice with nitrate removed for 12 weeks.

    Behavioral: Supervised Treadmill Exercise

  • Experimental
    Home-based walking exercise + nitrate rich beetroot juice

    This group will be participating in Home-Based Exercise and drinking nitrate rich beetroot juice for 12 weeks.

    Behavioral: Home-Based Exercise · Dietary Supplement: Nitrate-rich beetroot Juice

  • Placebo comparator
    Home-based walking exercise + placebo

    This group will be participating in Home-Based Exercise and drinking placebo beetroot juice with nitrated removed for 12 weeks.

    Behavioral: Home-Based Exercise

Interventions

  • BehavioralSupervised Treadmill Exercise

    This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.

  • BehavioralHome-Based Exercise

    This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.

  • Dietary supplementNitrate-rich beetroot Juice

    Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Six-Minute Walk Distance

    Change in six-minute walk distance

    Time frame: Measured at baseline and 12 week follow-up

Secondary outcomes

  1. Walking Impairment Questionnaire (WIQ) Distance Score

    WIQ distance score - Range 0-100, 100 is best.

    Time frame: measured at baseline and 12 weeks

  2. PROMIS Mobility Questionnaire Score

    PROMIS mobility score from administered PROMIS questionnaire. Score range is from zero to infinity and a higher score means a better outcome.

    Time frame: measured at baseline and 12 weeks

  3. 20-meter Improvement in Six-Minute Walk Distance

    Meaningful response to exercise interventions

    Time frame: measured at 12 weeks

  4. Step Count

    Step count measured over seven days with the FITBIT

    Time frame: measured at baseline and 12 weeks

  5. Six-Minute Walk Distance

    Change in six-minute walk distance

    Time frame: Measured at baseline and 24-week follow up

Other outcomes

  1. Physical Activity Step Count

    Step count measured over seven days with FITBIT

    Time frame: Measured at baseline and 24 weeks

  2. Physical activity distance

    Physical activity distance measured over seven days with FITBIT

    Time frame: Measured at baseline and 24 weeks.

  3. Short physical performance battery (SPPB)

    SPPB range, range 0-12, 12-best

    Time frame: measured at baseline and 12 weeks

  4. Walking Impairment Questionnaire (WIQ) Stair Climbing Score

    WIQ stair climbing score from administered WIQ, range 0-100, 100 is best.

    Time frame: measured at baseline and 12 weeks

  5. Walking Impairment Questionnaire (WIQ) Walking Speed Score

    WIQ walking speed score from administered WIQ, range 0-100, 100 is best

    Time frame: measured at baseline and 12 weeks

  6. Walking Impairment Questionnaire (WIQ) Stair Climbing Score

    WIQ stair climbing score from administered WIQ, range 0-100, 100 is best

    Time frame: measured at baseline and 24 weeks

  7. Walking Impairment Questionnaire (WIQ) Walking Speed Score

    WIQ walking speed score from administered WIQ, range 0-100, 100 is best

    Time frame: measured at baseline and 24 weeks

  8. Short physical performance battery (SPPB)

    SPPB range, range 0-12, 12-best

    Time frame: measured at baseline and 24 weeks

  9. Physical Activity Total Distance

    Distance walked over seven days measured with FITBIT

    Time frame: Measured at baseline and 12 weeks

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • McDermott MM, Cetlin MD, Domanchuk KJ, Xu S, Whipple MO, Polonsky T, Criqui MH, Guralnik JM, Tian L, Zhao L, Ho KJ, Greenland P, Treat-Jacobson D. Community-based recruitment with ankle brachial index testing to identify peripheral artery disease participants for randomized clinical trials. Am Heart J. 2026 Oct;300:107450. doi: 10.1016/j.ahj.2026.107450. Epub 2026 Apr 24. PubMed 42035974 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2028, 61 months after the start.

Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Sep 11, 2023
StartActual
Sep 8, 2023
Primary completionEst.
Nov 1, 2028
CompletionEst.
Mar 31, 2029
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06032065
Responsible party
Mary McDermott (Jeremiah Stamler Professor of Medicine, Northwestern University) — Principal investigator
First posted
Sep 11, 2023
Start date
Sep 8, 2023
Primary completion
Nov 1, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Apr 15, 2026

Study contacts

Mary McDermott, MD
Contact
mdm608@northwestern.edu
312-503-6438

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion